Jenck F, Moreau J L, Mutel V, Martin J R, Haefely W E
Pharma Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Eur J Pharmacol. 1993 Feb 9;231(2):223-9. doi: 10.1016/0014-2999(93)90453-o.
A variety of antidepressants of different chemical classes were tested for their in vivo and in vitro activity at 5-HT1C receptors in the brain. Conventional tricyclic antidepressants (imipramine, desipramine, maprotiline, clomipramine, trimipramine, amitriptyline, nortriptyline, doxepin, amoxapine) as well as mianserin and trazodone were found to display high to low nanomolar affinity for 5-HT1C receptors. Antidepressants of other chemical classes and with other mechanisms of action (affecting amine uptake systems: fluoxetine, citalopram, sertraline, fluvoxamine, nomifensine, amineptine; or monoamine oxidase inhibitors: moclobemide, iproniazid) had negligible affinities (micromolar range) for 5-HT1C receptors, except fluoxetine. When tested in an in vivo rat model thought to reveal functional agonistic or antagonistic properties at 5-HT1C receptors, all antidepressants displaying high affinity for this receptor type (except clomipramine and trimipramine) were antagonists at 5-HT1C receptors. Antidepressants with a lower affinity for 5-HT1C receptors (except nomifensine) were inactive in this functional in vivo model. Taken together, these results suggest that antagonism at brain 5-HT1C receptors is a component of the antiserotonergic properties of a number of established antidepressants. In addition, the study confirmed that 5-HT1A receptors functionally interact with 5-HT1C receptors, which suggests that some degree of activity at 5-HT1A receptors may also be an important property for antidepressant activity.
对多种不同化学类别的抗抑郁药进行了测试,以考察它们在脑内5-HT1C受体上的体内和体外活性。发现传统的三环类抗抑郁药(丙咪嗪、地昔帕明、马普替林、氯米帕明、曲米帕明、阿米替林、去甲替林、多塞平、阿莫沙平)以及米安色林和曲唑酮对5-HT1C受体具有高至低纳摩尔亲和力。其他化学类别和具有其他作用机制的抗抑郁药(影响胺摄取系统:氟西汀、西酞普兰、舍曲林、氟伏沙明、诺米芬辛、阿密替林;或单胺氧化酶抑制剂:吗氯贝胺、异烟肼)对5-HT1C受体的亲和力可忽略不计(微摩尔范围),但氟西汀除外。当在一种被认为可揭示5-HT1C受体功能激动或拮抗特性的体内大鼠模型中进行测试时,所有对该受体类型具有高亲和力的抗抑郁药(氯米帕明和曲米帕明除外)在5-HT1C受体上均为拮抗剂。对5-HT1C受体亲和力较低的抗抑郁药(诺米芬辛除外)在这种体内功能模型中无活性。综上所述,这些结果表明,脑内5-HT1C受体拮抗作用是许多已确立的抗抑郁药抗血清素能特性的一个组成部分。此外,该研究证实5-HT1A受体与5-HT1C受体在功能上相互作用,这表明5-HT1A受体的某种程度的活性也可能是抗抑郁活性的一个重要特性。